K-bio names making strides with promising clinical and review results in U.S. and Europe
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Daewoong Pharmaceutical recently said its botulinum toxin drug Nabota has demonstrated efficacy and safety in the treatment of patients with cervical dystonia in a phase 2 clinical trial conducted in the United States.
Oncology drug developer HLB was under limelight during the ESMO Congress held in Paris on Sept. 9-13. According to HLB, its liver cancer drug rivoceranib combined with camrelizumab demonstrated the world’s longest median overall survival (OS) in phase 3 clinical trials of liver cancer.
Genexine and Chong Kun Dang were other Korean names that grabbed attention at the ESMO Congress. Genexine’s investigational therapeutic DNA vaccine GX-188E GX-188E combined with Keytruda (pembrolizumab) showed an objective response rate of 31.7 percent in patients with HPV 16- and/or 18- positive advanced cervical cancer in a phase 1b/2 clinical study. The study provided a potential treatment option for patients suffering from the limited efficacy of existing immunotherapy regardless of their gene expression levels, said Genexine CEO Neil Warma.
Chong Kun Dang presented positive data from a phase 1 clinical trial of CKD-702, its investigational dual antibody cancer therapy, which is expected to be a solution for resistance to targeted cancer drugs.
Dong-A ST recently signed a global license deal with Nasdaq-listed NeuroBo Pharmaceuticals over its investigational diabetes drug and agreed to acquire an additional stake by investing $15 million to become the largest shareholder of the Boston-based biotech firm. Through the license deal, Dong-A ST will receive the company’s preferred stocks for $22 million in down payment and is eligible for development milestones worth up to $316 million.
Biosimilar giant Celltrion continues to expand its portfolio with new marketing approvals around the world.
Hype has been subdued as investors have seen many stagnation and flops despite successful clinical outcomes and licensing-out deals. Hanmi Pharmaceutical’s non-small cell lung cancer drug poziotinib, which was licensed out to U.S. partner Spectrum Pharmaceuticals is more likely to fail as the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 9-4 that the current benefits of the drug did not outweigh its risks last week.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Samsung, Intel, TSMC confirm alliance in next-gen “chiplet” technology - Pulse by Maeil Business News Korea
- Korean gov’t asks food manufacturers to refrain from rapid price hikes - Pulse by Maeil Business News Korea
- KEPCO bids for removal or hike in debt ceiling as it faces default crisis next year - Pulse by Maeil Business News Korea
- Moda Moda makes strides with hair-darkening shampoo abroad while regulated at home - Pulse by Maeil Business News Korea
- Samsung SDI cashes out of Ganfeng amid rising discrimination vs Chinese sourcing - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- ‘마통’ 만들면 신용점수 하락? ···오해와 진실
- “신혼여행 조식에 푹빠져” 미미♥천둥, “넓은 세상을 둘이 함께하니 너무 행복해” - MK스포
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이